A peptide-major histocompatibility complex ii chimera favors survival of pancreatic β-?slets grafted in type 1 diabetic mice

Transplantation

Volumn 85, Issue 12, 2008, Pages 1717-1725

  Casares, Sofia ^a,b   Lin, Marvin ^a   Zhang, Nan ^a   Teijaro, John R ^c   Stoica, Cristina ^d   McEvoy, Robert ^e   Farber, Donna L ^c   Bona, Constantin ^a   Brumeanu, Teodor D ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^e CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

Author keywords

Islets; Islets protection; Pancreas; Peptide MHC II chimera; Transplantation

Indexed keywords

HEMAGGLUTININ; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROTECTION; CELL SURVIVAL; CHIMERA; CONTROLLED STUDY; DISEASE COURSE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; ISOGRAFT; KIDNEY CAPSULE; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY CELL; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; POLARIZATION; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; ANIMAL; CELL PROLIFERATION; DIMERIZATION; DISEASE MODEL; GENE; GENETICS; HYPERGLYCEMIA; IMMUNOLOGY; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; TRANSPLANTATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHIMERA; DIABETES MELLITUS, TYPE 1; DIMERIZATION; DISEASE MODELS, ANIMAL; GENES, MHC CLASS II; GRAFT SURVIVAL; HEMAGGLUTININS; HYPERGLYCEMIA; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, TRANSGENIC; PEPTIDES; TH2 CELLS;

EID: 49149123257     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817752cc     Document Type: Article

References (56)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977.
2. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230.
3. Barshes NR, Lee T, Goodpasture S, et al. Achievement of insulin independence via pancreatic islet transplantation using a remote isolation center: A first-year review. Transplant Proc 2004; 36: 1127.
4. Ricordi C, Strom TB. Clinical islet transplantation: Advances and immunological challenges. Nat Rev Immunol 2004; 4: 259.
5. Ryan EA, Lakey JR, Paty BW, et al. Successful islet transplantation: Continued insulin reserve provides long-term glycemic control. Diabetes 2002; 51: 2148.
6. Morrison CP, Wemyss-Holden SA, Dennison A, et al. Islets yield remains a problem in islet autotransplantation. Arch Surg 2002; 137: 80.
7. Stagner JI, Rilo HL, White KK. The pancreas as an islet transplantation site. Confirmation in a syngeneic rodent and canine autotransplant model. J Pancreas 2007; 8: 628.
8. Ayres RC, Dousset B, Wixon S, et al. Peripheral neurotoxicity with tacrolimus. Lancet 1994; 343: 862.
9. Taler SJ, Textor SC, Canzanello VJ, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation 1996; 62: 1588.
10. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318.
11. Ryan EA, Paty BW, Senior A, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060.
12. Jun HS, Yoon JW. Approaches for the cure of type 1 diabetes by cellular and gene therapy. Curr Gene Ther 2005; 5: 249.
13. Gangaram-Panday ST, Faas MM, Vos P. Towards stem-cell therapy in the endocrine pancreas. Trends Mol Med 2007; 13: 164.
14. Hess D, Li L, Martin M, et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotech 2003; 21: 763.
15. Tang DQ, Cao LZ, Burkhardt BR, et al. In vivo and in vitro characterization of insulin-producing cells obtained from murine bone marrow. Diabetes 2004; 53: 1721.
16. Ende N, Chen R, Reddi AS. Effect of human umbilical cord blood cells on glycemia and insulitis in type 1 diabetic mice. Biochem Biophys Res Commun 2004; 17: 665.
17. Zhao Y, Wang H, Mazone T. Identification of stem cells from human umbilical cord blood with embryonic and hematopoietic characteristics. Exp Cell Res 2006; 312: 2454.
18. Yoshida S, Ishikawa F, Kawano N, et al. 2005. Human cord blood-derived cells generate insulin-producing cells in vivo. Stem Cells 2005; 23: 1409.
19. Okitsu T, Kobayashi N, Jun HS, et al. Transplantation of reversibly immortalized insulin-secreting human hepatocytes controls diabetes in pancreatectomized pigs. Diabetes 2004; 53: 105.
20. Soria B, Roche E, Berna G, et al. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes 2000; 49: 157.
21. Blyszczuk P, Czyz J, Kania G, et al. Expression of Pax4 in embryonic stem cells promotes differentiation of nestin-positive progenitor and insulin-producing cells. Proc Natl Acad Sci USA 2003; 100: 998.
22. Bromberg JS, Leroith D. Diabetes cure-is the glass half full? N Engl JMed 2006; 355: 1372.
23. Rossini AA, Mordes JP, Greiner DL, et al. Islet cell transplantation tolerance. Transplantation 2001; 72: S43.
24. Shapiro AM, Suarez-Pinzon WL, Power R, et al. Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice. Diabetologia 2002; 45: 224.
25. MolanoRD, PileggiA, BerneyT, et al. Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. Transplantation 2003; 75: 1812.
26. Berney T, Pileggi A, Molano RD, et al. The effect of simultaneous CD154 and LFA-1 blockade on the survival of allogeneic islet grafts in nonobese diabetic mice. Transplantation 2003; 76: 1669.
27. Casares S, Hurtado A, McEvoy RC, et al. Down-regulation of diabetogenic CD4 + T cells by a soluble dimeric peptide-MHC class II chimera. Nat Immunol 2002; 3: 383.
28. Casares S, Zong CS, Radu DL, et al. Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation. J Exp Med 1999; 190: 543.
29. Chen D, Zhang N, Fu S, et al. CD4 + CD25 + regulatory T-cells inhibit the islet innate immune response and promote islet engraftment. Diabetes 2006; 55: 1011.
30. Casares S, Bona CA, Brumeanu T-D. Engineering and characterization of a murine MHC class II-immunoglobulin chimera expressing an immunodominant CD4 T viral epitope. Protein Eng 1997; 10: 1295.
31. Ahmadzadeh M, Farber DL. Functional plasticity of an antigen-specific memory CD4 T cell population. Proc Natl Acad Sci USA 2002; 99: 11802.
32. Bingaman AW, Patke DS, Mane VR, et al. Novel phenotypes and migratory properties distinguish memory CD4 T cell subsets in lymphoid and lung tissue. Eur J Immunol 2005; 35: 3173.
33. Ndejembi MP, Teijaro JR, Patke DS, et al. Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol 2006; 177: 7698.
34. Tai MM. A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 1994; 17: 152.
35. Sutherland DE, Sibley R, Xu XZ, et al. Twin-to-twin pancreas transplantation: Reversal and reenactment of the pathogenesis of type 1 diabetes. Trans Assoc Am Physicians 1984; 97: 80.
36. van de Linde P, Vd Boog PJ, Tysma OM, et al. Selective unresponsiveness to beta cells autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin. Clin Exp Immunol 2007; 149: 56.
37. Kobayashi T, Aomatsu Y, Iwata H, et al. Survival of microencapsulated islets at 400 days postransplantation in the omental pouch of NOD mice. Cell Transplant 2006; 15: 359.
38. Koulmanda M, Qipo A, Auchincloss H, et al. Effects of streptozotocin on autoimmune diabetes in NOD mice. Clin Exp Immunol 2003; 134: 210.
39. Chong AS, Shen J, Tao J, et al. Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration. Science 2006; 311: 1774.
40. Nishio J, Gaglia JL, Turvey SE, et al. Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution. Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution. Science 2006; 311: 1775.
41. Suri A, Calderon B, Esparza TJ, et al. Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells. Science 2006; 311: 1778.
42. Moulton VR, Bushar ND, Leeser DB, et al. Divergent generation of heterogeneous memory CD4 T cells. J Immunol 2006; 177: 869.
43. Bradley LM, Asensio VC, Schioetz LK, et al. Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J Immunol 1999; 162: 2511.
44. Gallichan WS, Balasa B, Davies JD, et al. Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. J Immunol 1999; 163: 1696.
45. Shi Q, Wangm D, Hadley GA, et al. Long-term islet graft survival in NOD mice by abrogation of recurrent autoimmunity. Diabetes 2004; 53: 2338.
46. Viglietta V, Kent SC, Orban T, et al. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest 2002; 109: 895.
47. Waid DM, Wagner RJ, Putnam A, et al. A unique T cell subset described as CD4loCD40+ T cells (TCD40) in human diabetes. Clin Immunol 2007; 124: 138.
48. WulffH, PenningtonM. Targeting effector memory T-cells with Kv1.3 blockers. Curr Opin Drug Discov Dev 2007; 10: 438.
49. Herzog BA, Ott PA, Dittrich MT, et al. Increased in vivo frequency of IA-2 peptide-reactive IFNgamma in type 1 diabetic subjects. J Auto immun 2004; 23: 45.
50. Ott PA, Berner BR, Herzog BA, et al. CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cells in human diseases. J Immunol Methods 2004; 15: 223.
51. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887.
52. Zhang Q, Chen Y, Fairchild RL, et al. Lymphoid sequestration of allo-reactive memory CD4 T cells promotes cardiac allograft survival. J Immunol 2006; 176: 770.
53. Ndejembi MP, Tang AL, Farber DL. Reshaping the past: Strategies for modulating T-cell memory immune responses. Clin Immunol 2007; 122: 1.
54. Todd JA, Wicker LS. Genetic protection from the inflammatory disease type 1 diabetes in humans and animal models. Immunity 2001; 15:387.
55. Sanjeevi CB, Hook P, Landin-Olsson M, et al. DR4 subtypes and their molecular properties in a population-based study of Swedish childhood diabetes. Tissue Antigens 1996; 47: 275.
56. Preda I, McEvoy RC, Lin M, et al. Soluble, dimeric HLA DR4-peptide chimeras: An approach for detection and immunoregulation of human type-1 diabetes. Eur J Immunol 2005; 35: 2762.